Cargando…

Insulin-like Growth Factor 1 Receptor Expression in Advanced Non-small-cell Lung Cancer and its Impact on Overall Survival

BACKGROUND: The insulin-like growth factor 1 receptor (IGF1R) expression has been addressed as a potential prognostic marker in non-small-cell lung cancer (NSCLC) in various studies; however, the associations between IGF1R expression and prognosis of advanced NSCLC patients is still controversial. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Humar, Mojca, Kern, Izidor, Vlacic, Gregor, Hadzic, Vedran, Cufer, Tanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter Open 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514660/ https://www.ncbi.nlm.nih.gov/pubmed/28740455 http://dx.doi.org/10.1515/raon-2017-0020

Ejemplares similares

Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival
por: Stanic, Karmen, et al.
Publicado: (2014)

High BMI1 mRNA expression in peripheral whole blood is associated with favorable prognosis in advanced non-small cell lung cancer patients
por: Koren, Ana, et al.
Publicado: (2017)

PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung
por: Janzic, Urska, et al.
Publicado: (2017)

Real-life Long-term Outcomes of Upfront Surgery in Patients with Resectable Stage I-IIIA Non-small Cell Lung Cancer
por: Bitenc, Marko, et al.
Publicado: (2022)

Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins PHD1 and PHD2 but Not PHD3 Are Decreased in Primary Tumours and Correlate with Poor Prognosis of Patients with Surgically Resected Non-Small-Cell Lung Cancer
por: Koren, Ana, et al.
Publicado: (2021)

BMI1, ALDH1A1, and CD133 Transcripts Connect Epithelial-Mesenchymal Transition to Cancer Stem Cells in Lung Carcinoma
por: Koren, Ana, et al.
Publicado: (2016)

Expression of FGFR1–4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity
por: Vlacic, Gregor, et al.
Publicado: (2019)

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
por: Pelicon, Veronika, et al.
Publicado: (2023)

Insulin resistance, lipids and body composition in patients with coronary artery disease after combined aerobic training and resistance training: a randomised, controlled trial
por: Kambic, Tim, et al.
Publicado: (2023)

Oral treatment with etoposide in small cell lung cancer – dilemmas and solutions
por: Rezonja, Renata, et al.
Publicado: (2013)

The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer
por: Sodja, Eva, et al.
Publicado: (2016)

Idiopathic Pulmonary Fibrosis in Patients with Early-stage Non-small-cell Lung Cancer after Surgical Resection
por: Nezka, Hribernik, et al.
Publicado: (2019)

Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists
por: Brcic, Luka, et al.
Publicado: (2020)

Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
por: Vrankar, Martina, et al.
Publicado: (2020)

Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
por: Omersa, Daniel, et al.
Publicado: (2016)

P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment
por: Pezzuto, Federica, et al.
Publicado: (2021)

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients
por: Kukec, Renata Rezonja, et al.
Publicado: (2015)

Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor
por: Minami, Seigo, et al.
Publicado: (2017)

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
por: Zwitter, Matjaz, et al.
Publicado: (2016)

Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting
por: Lekic, Mirko, et al.
Publicado: (2012)

Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
por: Zwitter, Matjaz, et al.
Publicado: (2014)

Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer
por: Pan, Mingmei, et al.
Publicado: (2021)

Biology of Metastasis With Focus on Proteases
por: Cufer, Tanja
Publicado: (2005)

Intermittent Chemotherapy and Erlotinib for Nonsmokers or Light Smokers with Advanced Adenocarcinoma of the Lung: A Phase II Clinical Trial
por: Zwitter, Matjaz, et al.
Publicado: (2011)

Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis
por: Chen, Yunzhen, et al.
Publicado: (2013)

Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
por: Crawford, Jeffrey, et al.
Publicado: (2019)

Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China
por: Ma, Yuhui, et al.
Publicado: (2023)

Spirometry at diagnosis and overall survival in non‐small cell lung cancer patients
por: Zhai, Ting, et al.
Publicado: (2022)

The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer
por: Zhang, Jian-Wei, et al.
Publicado: (2014)

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2017)

Predictive value of pretreatment albumin‐to‐alkaline phosphatase ratio for overall survival for patients with advanced non‐small cell lung cancer
por: Zhou, Shaozhang, et al.
Publicado: (2020)

Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
por: Ton, Thanh G.N., et al.
Publicado: (2022)

Advanced Cervical Cancer: Leveraging the Historical Threshold of Overall Survival
por: Paulino, Eduardo, et al.
Publicado: (2021)

Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
por: Yamamoto, Takaya, et al.
Publicado: (2022)

Relationship between insulin-like growth factor-1 and cerebral small vessel disease and its mechanisms: advances in the field
por: Du, Hao, et al.
Publicado: (2023)

The Impact of Social Determinants of Health, Namely Financial Assistance, on Overall Survival in Advanced-Stage Non-Small Cell Lung Cancer Patients
por: Bello, Andreas, et al.
Publicado: (2023)

Allergic bronchopulmonary aspergillosis with coexistant aspergilloma: a case report
por: Kern, Izidor, et al.
Publicado: (2010)

Clinical significance of histologic subtyping of malignant pleural mesothelioma
por: Brcic, Luka, et al.
Publicado: (2020)

Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival
por: Catrina, S-B, et al.
Publicado: (2005)

Role of Insulin-like Growth Factor, Insulin-like Growth Factor Receptors, and Insulin-like Growth Factor-binding Proteins in Ovarian Cancer
por: Amutha, Periyasamy, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tpiumq1pavt658rlsm76thn7l9